Introduction: Detection of somatic genomic alterations in the plasma of patients with cancer ("liquid biopsy") are increasingly being used in the clinic. However, the concordance of alterations identified in liquid biopsies with those detected in cancer specimens is not routinely being determined.
Methods:
We sought to systematically compare alterations found by a massively parallel sequencing liquid biopsy assay covering 39 genes (NEOliquid [NEO New Oncology GmbH, Köln, Germany]) with those identified through routine diagnostic testing in a certified central pathology laboratory in a cohort of patients with nonsquamous NSCLC. NEOliquid is based on enrichment of the genomic territory of interest by hybrid capture and is thus capable of detecting point mutations, small insertions and deletions, copy number alterations, and gene rearrangements/fusions in a single assay.
Results: In a cohort of 82 patients with matched blood/ tissue samples, the concordance between NEOliquid and tissue-based routine testing was 98%, the sensitivity of NEOliquid was higher than 70%, and the specificity was 100%. Discordant cases included those with insufficient amounts of circulaating tumor DNA in plasma and cases in which known driver mutations (e.g., isocitrate dehydrogenase (NADP(þ)), 1 14) were found in the plasma but were not interrogated by routine tissue analyses.
Conclusions: In summary, NEOliquid offers accurate and reliable detection of clinically relevant driver alterations in plasma of patients with cancer.
Introduction
The past decade has witnessed a dramatic change in the clinical care of patients with cancer. In several tumors, somatic genomic alterations have been discovered that cause exquisite dependency of cancer cells on the resulting genetically activated signaling pathways. Frequently, these alterations affect kinases or activate kinase pathways, which have emerged as effective drug targets that can be therapeutically addressed with high activity and selectivity. Accordingly, treatment of patients whose tumors bear such targetable alterations results in high response rates and prolongation of progression-free survival. Examples include not only EGFR-mutant, ALK receptor tyrosine kinase gene (ALK)-rearranged, and ROS1-rearranged lung cancers, but also other cancers such as BRAF-mutant melanoma, erb-b2 receptor tyrosine kinase 2 gene (ERBB2)-amplified breast cancer, and KIT proto-oncogene receptor tyrosine kinas gene (KIT)-mutant gastrointestinal stromal tumors. [1] [2] [3] [4] [5] [6] Today, genotyping of patients with cancer has thus become a clinical routine in certain tumor types. However, some of these alterations also occur across multiple tumor types (e.g., BRAF mutations), thus necessitating comprehensive tumor genotyping across all possibly affected tumors. Current diagnostic approaches include polymerase chain reaction (PCR)-based massively parallel next-generation sequencing (NGS)-based sequencing for detection of somatic mutations, which is typically complemented by fluorescence in situ hybridization (FISH) for detection of copy number alterations or rearrangements. This approach, however, is limited by factors such as low sensitivity of FISH in detecting rearrangements (approximately 70%), 7, 8 tissue availability and amount, and prolonged turnaround time. By contrast, hybrid capture-based comprehensive (thirdgeneration) cancer genome analysis offers the advantage of determining all therapeutically relevant alterations in a single sequencing analysis, thus saving time and tissue. 9 Simultaneously, the sensitivity for detection of kinase rearrangements (e.g., in ALK) is greatly enhanced. Thus, third-generation tumor genotyping offers clinically relevant advantages over other assays.
Probably as a result of cellular turnover, cancer cells release their DNA (circulating tumor DNA [ctDNA]) into the bloodstream of patients with cancer, contributing to the overall amount of cell-free DNA (cfDNA) in the blood circulation. The amount of ctDNA is directly proportional to the overall tumor burden 10 and is an independent prognosticator of disease. 11 Furthermore, multiple approaches have been developed with the goal of identifying therapeutically relevant cancer genome alterations in blood samples, thus sparing patients from invasive biopsy procedures. 12 Overall, the use of liquid biopsy is increasingly becoming part of clinical guidelines. 13 Similar to the aforementioned conventional cancer genotyping methods, these assays rely on PCR-based amplification of target regions. Although these assays are sensitive in the detection of point mutations, they are not comprehensive, as they lack the technical prerequisites to detect copy number alterations and rearrangements/gene fusions. However, the full spectrum of clinically relevant alterations is becoming of ever-increasing importance for clinical decision making. For example, acquired resistance to EGFR inhibition may be caused by the T790M mutation, by amplification of MNNG HOS Transforming gene (MET), or both. Each of these genotypes, however, requires a different therapeutic intervention: T790M-bearing tumors can still be treated effectively with the third-generation EGFR inhibitor osimertinib, 14 whereas the presence of a MET amplification might require the addition of a mesenchymal-epithelial transition (MET) inhibitor.
We recently developed NEOliquid (NEO New Oncology GmbH, Köln, Germany), a comprehensive hybrid capture-based NGS cancer genotyping assay for parallel detection of point mutations, small insertions and deletions (InDels), copy number alterations, and rearrangements/gene fusions in plasma samples obtained from patients with cancer. This assay covers 39 clinically relevant genes (Supplementary Data 1A) and has been optimized for use with commercially available plasma collection tubes for seamless routine clinical use. Here, we describe a thorough clinical concordance study in which we compare results generated with NEOliquid using plasma of patients with cancer with those generated by clinical routine testing (PCR-based testing and FISH) of formalin-fixed, paraffin embedded (FFPE) tissue obtained from the same patients. In case any material was left after routine testing, additional tissue analysis was performed by using NEOplus, a hybrid capturebased NGS test developed to detect genomic alterations in 94 genes (Supplementary Data 1B).
Methods

Routine Testing
Specimens obtained from patients with nonsquamous NSCLC collected within the German Lung Cancer Network NOWEL were analyzed. The Institute for Hematopathology Hamburg evaluated routine diagnostic FFPE samples for tumor content, and DNA was extracted (Maxwell cat.# AS1135 [Promega, Madison, WI]) after manual macrodissection. In cases in which tumor content was limited, tumor cells were enriched by laser microdissection (Leica LMD 6500 laser microdissection system [Leica Biosystems, Nussloch, Germany]). EGFR exon 18 to 21 mutational analysis was performed using the cobas EGFR Mutation Test (Roche Molecular Diagnostics, Pleasanton, CA), covering the 41 most common EGFR mutations. KRAS (exons 2 and 3) and TP53 (exons 5 to 9) mutations were analyzed using Sanger sequencing. BRAF codons V600 and G469 were analyzed by real-time PCR. ALK and ROS1 translocations were first indirectly screened by immunohistochemistry (Platform Leica Bond III platform [Roche]) using antibodies against ALK (clone D5F3 [New England Biolabs, Ipswich, MA]) and ROS1 (clone D4D6 New England Biolabs). Immunohistochemical results were confirmed by in situ hybridization (FISH), using ALK (Dako, Carpenteria, CA) and ROS1 (Leica Biosystems) break-apart probes.
NEOplus
After pathological review, genomic DNA was extracted from 5 to a maximum of 15 sections (10 mm) of FFPE material, with a tumor content of 10% or more. From 100 to 200 ng of sheared DNA (Covaris, Woburn, MA) was subjected to hybrid capture-based NGS to detect point mutations, small InDels, copy number alterations, and rearrangement/gene fusions in a single assay (NEOplus) (see Supplementary Data 1B). In brief, after shearing, adapters were ligated and the individual genomic regions of interest were enriched using complementary bait sequences (hybrid capture procedure). The selected baits ensured optimal coverage of all relevant genomic regions. After enrichment, targeted fragments were amplified (clonal amplification) and sequenced in parallel with an average mean sequencing depth of 1713Â (unfiltered reads). Computational analysis was performed using NEO New Oncology's proprietary computational biology analysis pipeline to detect relevant genomic alterations in a quantitative manner (minor allele frequencies [MAFs] !5%).
NEOliquid
Whole blood (18 mL) was collected in Streck tubes (Cell-Free DNA BCT, Streck, Omaha, NE) and cfDNA was extracted using Qiagen's QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany). cfDNA (average size approximately 160 base pairs) was subjected to hybrid capture-based NGS to detect point mutations, small InDels, copy number alterations, and genomic translocations in a single assay (NEOliquid) (see Supplementary Data 1A). In brief, after DNA extraction, adapters were ligated and DNA processed as described earlier. After enrichment, targeted fragments were amplified (clonal amplification) and sequenced in parallel at an ultrahigh sequencing depth averaging 37,150Â (unfiltered reads). Computational analysis was performed with NEO New Oncology's proprietary computational biology analysis pipeline to remove sequencing artifacts and detect relevant genomic alterations in a quantitative manner (MAFs !0.1%).
Statistical Methods
Sensitivity was calculated using the following formula: 
Patient Selection/Consent
Eligible patients had a histological/cytological confirmed diagnosis of nonsquamous NSCLC. For all patients, a tissue biopsy was available for testing. Samples of patients with tumors responding to targeted drug treatment at the time of blood withdrawal were excluded. All samples were collected under institutional review board approval and informed patient consent.
Results
In total, 98 patients with NSCLC were enrolled in this concordance study. Of these, 95 were of the nonsquamous histological subtype and three were not otherwise specified. 15 The mean age in the cohort was 66 years (44% male versus 56% female patients) (Fig. 1A) . All patient specimens were analyzed by routine diagnostic methods. Depending on availability, NEOplus or NEOliquid on either FFPE material or a corresponding blood sample was performed to evaluate the concordance between the respective diagnostic methods.
We performed a routine diagnostic genetic work-up in a certified central pathology testing laboratory for somatic hotspot mutations in BRAF, EGFR, and KRAS, as well as for genomic rearrangements in ALK and ROS1. Testing was performed in a sequential manner and included commercially available PCR-based kits and laboratory-developed tests for detection of exonic mutations as well as FISH for detection of ALK and ROS1 rearrangements. We identified a total of 54 somatic genomic alterations in these patients, of which 41 mutations were point mutations, 13 were small InDels (e.g., those affecting exon 19 [n¼11] or 20 [n¼2] of EGFR), and three were gene fusions affecting the ALK or ROS1 genes (Supplementary Data 2) . In 53% of the cases, routine diagnostic tissue testing identified a driver mutation.
Of the 98 specimens, 75 had sufficient tissue left for hybrid capture-based NGS (NEOplus). The comparison between NEOplus and routine testing was restricted to genetic alterations affecting the analytical territory of the latter. Genomic regions not covered by conventional testing were excluded from analysis. Of those 75 samples, 36 point mutations, 11 InDels, and two gene fusions were detected by routine testing, all of which were confirmed by NEOplus analysis (Supplementary Data 2 and Fig. 1B-D) .
Two tissue samples tested as wild type for KRAS mutations in conventional tissue testing were identified as harboring a KRAS mutation by NEOplus (with MAFs of 10% and 11%, respectively). Both mutations were sequenced at sufficiently high coverage (>500Â), suggesting accurate mutation calling despite limited amounts of tissue (Supplementary Data 3A) . Because of the technical limitation of Sanger sequencing to detect mutations at low MAFs, 16 these two mutations were not considered for our concordance analysis.
Thus, we observed a concordance of 100% with a sensitivity of 100% and a specificity of 100% (Fig. 1E  and Supplementary Data 2) .
Furthermore, NEOplus testing identified multiple driver or resistance mutations that were not covered by routine hotspot testing. These included the C797 residue of EGFR-known to be implicated in resistance to the third-generation EGFR inhibitor-in a patient with acquired resistance to osimertinib, 17 ERBB2 and EGFR amplifications, MET exon 14 skipping mutations, and likely activating gene fusions in BRAF and MET.
Of the 98 patients tested initially, 82 had available peripheral blood, all of which was tested using NEOliquid. Analysis of the liquid biopsies revealed a total of 26 point mutations, 10 InDels, and one ALK translocation within the same analytical territory as defined earlier ( Supplementary Data 2 and 3B ). These included 17 targetable driver alterations, for which a kinase inhibitor is currently available. Additional mutations were identified in KRAS, a common oncogenic driver in lung adenocarcinoma without any approved therapy options and in other genes ( Fig. 2A) . Overall, the concordance of mutation calls between routine diagnostic testing and NEOliquid was 97.6%, with a sensitivity of 70.8% and a specificity of 100% (Fig. 2B  and Supplementary Data 2) .
Careful evaluation of the cases in which the application of NEOliquid did not identify the genomic alteration detected in the tissue specimen revealed insufficient ctDNA within the extracted cfDNA as the most likely reason for these false-negative mutation calls. As an example, in three out of three samples, multiple mutations per sample (such as additional TP53 mutations identified in the tissue specimen) were commonly not identified in plasma, suggesting a complete absence of ctDNA in these blood samples. In line with this notion, we compared the distribution of allele frequencies of all somatic mutations identified by NEOplus and NEOliquid, and as expected, we found the most abundant allele frequency as identified by NEOliquid in the MAF range from 0.1% to 1% (Fig. 2C) .
Furthermore, the abundance of cfDNA correlated with the presence or absence of metastases (Fig. 2D) . In line with this finding, sensitivity was higher (74%) in patients with distant metastases (M1b). Unfortunately no genomic alterations were detected in M0 samples by routine testing, thus restricting sensitivity to M1a and M1b cases. Independent of the presence of metastases, the specificity of NEOliquid-based mutation detection was always 100% across all alterations that were covered by routine testing. In addition, in four out of 46 pan-negative routine tissue samples NEOliquid revealed clinically relevant and actionable genomic alterations not covered by routine testing (see Fig. 2A and B) . These included one ERBB2 G776delinsVC, two MET exon 14 skipping mutations, and a RET rearrangement. [18] [19] [20] In February 2014, stage IV lung cancer with CNS metastases and absence of alterations in EGFR, ALK, and KRAS was diagnosed in the patient harboring the kinesin family member 5B gene (KIF5B)-RET gene fusion (Fig. 3A) . After multiple rounds of irradiation and systemic cytotoxic treatment, NEOliquid was performed in November 2015, revealing the KIF5B-RET rearrangement. Based on this result, in February 2016, cabozantinib was administered at a dose of 140 mg, resulting in a partial remission (42% shrinkage) of the tumor (Fig. 3B) .
Additional mutations identified by NEOliquid included activating mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) and catenin beta 1 gene (CTNNB1), amplifications of EGFR as well as inactivating alterations in tumor suppressor genes (e.g., tumor protein p53 gene [TP53] and serine/threonine kinase 11 gene [STK11]) (see Fig. 2A and Supplementary Data 4) . Furthermore, in one patient with an activating EGFR L858R mutation detected in the original tissue specimen through routine diagnostic testing, an oncogenic isocitrate dehydrogenase (NADP(þ)), 1 systolic gene (IDH1) R132H mutation was identified in the plasma, possibly indicating the presence of two primary tumors. On the basis of issue testing, the patient was treated with an EGFR inhibitor but died soon thereafter.
Thus, in addition to providing comprehensiveness in detecting all types of therapeutically relevant cancer genome alterations in the most relevant genes, NEOliquid also serves as an unbiased approach for the detection of rare or novel driver alterations that would have otherwise been missed by routine diagnostic testing (see Fig. 2A and B and Table 1 ).
Discussion
We have presented one of the first systematic concordance analysis of comprehensive liquid biopsy and tissue-based testing in a routine clinical setting. 21, 22 All samples were collected within the Lung Cancer Network NOWEL, a Germany-wide association of lung cancer centers and oncology practices with access to comprehensive hybrid capture-based liquid biopsy testing for all members. Our comparison with routine testing (PCR-based assay plus FISH) revealed a concordance higher than 98% and a specificity and PPV of 100% for liquid biopsy (NEOliquid), as well as 100% concordance for tissue-based testing with NEOplus. Furthermore, we identified a broad range of targetable genomic alterations, both in liquid biopsies and in tissue biopsies by performing comprehensive hybrid capturebased sequencing. Clinical responses to targeted therapies based on these findings underline the importance of comprehensive testing for the individual patient (see Fig. 3B ).
Despite the high concordance in calling mutations and the excellent PPV, the sensitivity of all liquid biopsy tests is strongly affected by the tumor burden. 10, 14, 23, 24 As a consequence, in those cases in which recurrent disease is driven by a small number of resistant tumor cells, liquid biopsies may miss the relevant mutations. Despite the limited number of samples, this effect is emphasized by the enhanced sensitivity (74% [n ¼ 48]) in patients with metastatic disease (M1b). Furthermore, we note that the samples in our study were collected without filtering for time of surgery and blood withdrawal. As a consequence, in several sample pairs there was a considerable time lapse between tissue and liquid biopsy (Supplementary Data 3C), which may explain the marked differences of mutational burden in the blood. We beleive, however, that such lack of selection may more appropriately reflect the clinical reality in testing patients. Thus, a negative result from a liquid biopsy test may in general be considered noninformative. By contrast, the excellent PPV of NEOliquid in calling actionable alterations offers highly accurate and reliable recommendations for treatment. In addition, because of the comprehensiveness of NEOliquid, the relevant driver alteration was detected in 49% of all plasma samples (compared with in 53% by routine tissue testing [see Table 1 and Supplementary Data 2] ). In summary, we have shown the almost universal concordance of a comprehensive plasma-based cancer genotyping test, NEOliquid, with tests assessing cancer genome alterations in tumor tissue specimens. The excellent PPV of actionable alterations identified by NEOliquid offers high analytical performance for routine diagnostic use. n/a, not applicable.
